MedTrace Logo

Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer

NCT00036868 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-03-08

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy such as cyclophosphamide, methotrexate, and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with trastuzumab may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining combination chemotherapy with trastuzumab in treating women who have metastatic breast cancer.

Conditions

Interventions

BIOLOGICAL

trastuzumab

DRUG

CMF regimen

DRUG

cyclophosphamide

DRUG

fluorouracil

DRUG

methotrexate

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • David Cameron · Western General Hospital, Edinburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Primary Completion
2009-06-30
Completion
2010-02-28

Countries

  • Belgium
  • Denmark
  • Egypt
  • France
  • Netherlands
  • Poland
  • Serbia
  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00036868 on ClinicalTrials.gov